US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Articles published by Galderma

< Previous 1 2 3 4 Next >
News headline image
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
From Galderma
Via Business Wire
News headline image
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership
From Galderma
Via Business Wire
News headline image
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis
From Galderma
Via Business Wire
News headline image
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering
From Galderma
Via Business Wire
News headline image
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing
From Galderma
Via Business Wire
News headline image
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older
From Galderma
Via Business Wire
News headline image
30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation
From Galderma
Via Business Wire
News headline image
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis
From Galderma
Via Business Wire
News headline image
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
From Galderma
Via Business Wire
News headline image
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies
From Galderma
Via Business Wire
News headline image
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing
From Galderma
Via Business Wire
News headline image
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
From Galderma
Via Business Wire
News headline image
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region
From Galderma
Via Business Wire
News headline image
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns
From Galderma
Via Business Wire
News headline image
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
From Galderma
Via Business Wire
News headline image
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments
From Galderma
Via Business Wire
News headline image
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
From Galderma
Via Business Wire
News headline image
Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform
From Galderma
Via Business Wire
News headline image
Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause
From Galderma
Via Business Wire
News headline image
Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare
From Galderma
Via Business Wire
News headline image
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs
From Galderma
Via Business Wire
News headline image
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing
From Galderma
Via Business Wire
News headline image
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting
From Galderma
Via Business Wire
News headline image
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies
From Galderma
Via Business Wire
News headline image
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering
From Galderma
Via Business Wire
News headline image
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin
From Galderma
Via Business Wire
News headline image
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
From Galderma
Via Business Wire
News headline image
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics
From Galderma
Via Business Wire
News headline image
Galderma Announces Appointment of New Chief Financial Officer
From Galderma
Via Business Wire
News headline image
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties
From Galderma
Via Business Wire
< Previous 1 2 3 4 Next >